Arrowhead Wins Phase 3 Plozasiran Trial in Severe Hypertriglyceridemia, Pressuring Ionis Shares
Updated
Updated · Seeking Alpha · Jul 22
Arrowhead Wins Phase 3 Plozasiran Trial in Severe Hypertriglyceridemia, Pressuring Ionis Shares
3 articles · Updated · Seeking Alpha · Jul 22
Summary
Arrowhead Pharmaceuticals said its lipid-lowering drug plozasiran met goals in a late-stage trial for patients with severe hypertriglyceridemia, marking a key clinical win for the company.
The result strengthens Arrowhead's position in a market where Ionis Pharmaceuticals already sells a rival therapy, and Ionis shares fell after the announcement.
Plozasiran targets dangerously high triglyceride levels, and the Phase 3 success could support Arrowhead's push toward regulatory filings and a broader commercial challenge in rare lipid disorders.